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Aims To describe clinical and demographic characteristics at baseline of a European cohort of adults
with congenital heart disease (CHD) and to assess mortality and morbidity in a 5 year follow-up period.
Methods and results Data collected as part of the Euro Heart Survey on adult CHD was analysed. This
entailed information transcribed from the ﬁles of 4110 patients diagnosed with one of eight congenital
heart conditions (‘defects’), who consecutively visited the outpatient clinics of one of the participating
centres in 1998. The patients were included retrospectively and followed until the end of 2003 for a
median follow-up of 5.1 years. Notwithstanding their overall relatively good functional class and low
mortality over the follow-up period, a considerable proportion of the patients had a history of endocar-
ditis, arrhythmias, or vascular events. There were major differences between the eight defects, both in
morbidity and regarding speciﬁc characteristics. Outcomes were worst in cyanotic defects and in the
Fontan circulation, but a considerable proportion of the other patients also suffer from cardiac symp-
toms. In particular, arrhythmias are common.
Conclusion The spectrum of adult CHD in Europe emerging from this survey is one of a predominantly
young population with substantial morbidity but relatively low mortality in a 5 year period.
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Introduction
The Euro Heart Survey (EHS) programme provides a
structured context for gathering information on large, inter-
national, patient populations in a ‘realistic’ setting of actual
day-to-day clinical decision making. The perspectives
opened thereby are especially attractive in the ﬁeld of con-
genital heart disease (CHD), in which scarcity of data is the
norm rather than the exception. The existence of a substan-
tial population of adults born with a cardiac defect is a rela-
tively new phenomenon that has resulted from advances in
paediatric cardiology, cardiac surgery, and other subspecial-
ties over the past few decades. Adults with CHD are often
faced with symptoms, sequelae, and complications from
residual defects and interventions, including arrhythmias,
congestive heart failure, endocarditis, psycho-social
problems, and early death. However, epidemiological
characteristics of this population, needs for care, and clini-
cal outcome are still poorly known. In contrast to other car-
diovascular diseases, not more than a few multi-centre trials
have been performed and there have been no large random-
ized trials addressing treatment strategies. Thus, current
guidelines for the management of adults with CHD are
based mainly on non-randomized studies, case series, and
results of consensus conferences.1–6
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Considering the aforementioned issues, the European
Society of Cardiology has supported this survey to describe
the spectrum of disease and outcomes in adults with CHD
and to evaluate the role of guidelines in clinical practice.
Reporting on the results of this EHS, this article describes
the patient population and the manifestation of morbidity
and mortality in a 5 year follow-up period.
Methods
The set-up of the study was devised and monitored by an expert
committee. The existing EHS network was used for recruitment of
centres and data entry. Overall data management was conducted
by the staff of the Heart House in Sophia Antipolis in France.
Design of the survey
Considering the low prevalence of the various defects and low fre-
quency of cardiovascular events, the survey was designed as a retro-
spective cohort study. Consecutive patients fulﬁlling the inclusion
criteria (see what follows) were included retrospectively at their
ﬁrst visit to the outpatient clinic in 1998 (or else 1999 or 2000)
and their follow-up data until April 2004 were recorded reviewing
the medical chart. Patients were included by the local investigators.
Patients (inclusion criteria)
According to the protocol, all patients aged .17 years who had a
diagnosis of one of the following eight congenital cardiac conditions
(‘defects’) were included: cyanotic disease, Fontan circulation (i.e.
status after the Fontan operation, a palliative intervention in
patients with a single functional ventricle), tetralogy of Fallot,
aortic coarctation (CoA), complete transposition of the great
arteries (TGA), Marfan syndrome, ventricular septal defect (VSD),
or secundum atrial septal defect (ASD). If more than one diagnosis
applied, the diagnosis appearing ﬁrst in the order in which they
are listed earlier was chosen as the main diagnosis (but in the
case of ASD and VSD, the more severe of the two).
Centres
Centres were identiﬁed from the lists of European hospitals with
facilities for care of adults with CHD, provided by the national co-
ordinators of the EHS programme, and through the Working Group
on Grown-Up Congenital Heart Disease of the European Society of
Cardiology. Contact persons were approached by e-mail. In addition,
the survey was advertized on the EHS website and in the European
Society of Cardiology’s web news. Participation was on a voluntary
basis and both specialized (see what follows) and non-specialized
centres following a substantial population of adult patients with
CHD were included.
Specialized centres were deﬁned as tertiary referral centres
meeting all three of the following criteria: availability of paediatric
cardiology or congenital cardiac surgery, at least one cardiologist
dedicated to adult CHD, and at least 200 congenital outpatient
visits per year.
Data collection and entry
Demographical and clinical data were derived from patients’
medical records and entered online in a web-based electronic
case record form (CRF). The CRF was developed under the auspices
of the Expert Committee and data were entered by the investigators
themselves or by specially trained data collection ofﬁcers.
Patient data were entered anonymously, with only a number to
identify the centre and another indicating the order of entry. The
CRF was supplied with a software-implemented utility for auto-
mated checking of data for consistency and completeness and to
ensure that values were not excessively out of the normal range.
The electronic ﬁles were managed by the data management staff
at the European Heart House, who also performed additional
queries in case of missing, incomplete, or ‘outlying’ data. The data-
base was opened on 1 July 2003 and closed on 30 April 2004.
Data collected
The following data were collected: a general section of the CRF
assessed demographic data; the use of medication; diagnostic pro-
cedures performed during follow-up; clinical baseline character-
istics (such as functional status) and history of endocarditis,
arrhythmias, or vascular events; pregnancies; and vital status at
the end of follow-up. Arrhythmias considered were supraventricular
arrhythmias and ventricular arrhythmias, but premature beats were
excluded.
In separate sections devoted to the individual defects, defect-
speciﬁc diagnostic ﬁndings (both quantitative and qualitative) at
study entry as well as changes in the parameters assessed, which
occurred during follow-up, were to be recorded. In addition, it
was required to indicate which interventions (surgical or transcath-
eter) had been performed before study entry and during follow-up.
Data analysis
The ﬁnal database was sent for analysis to the EHS adult CHD data
analysis centre at the Academic Medical Centre in Amsterdam.
Statistical methods used were mainly descriptive. Categorical
variables are presented as percentages and numbers: continuous
variables as means (standard deviation) for normally distributed vari-
ables and as medians (interquartile range) for non-normally
distributed data. Mortality in the follow-up period was analysed
with the Kaplan–Meier method; the log rank test was used to
test whether mortality was different among the groups, accepting
a P value, 0.05 as signiﬁcant. Outcomes of reproductive behaviour
in women were assessed by calculating the percentages of females
who had at least one full-term pregnancy before the end of follow-
up. The corresponding measure for a hypothetical age-matched
sample of the general Dutch population was calculated using life-
tables made available by the national statistical bureau (Statistics
Netherlands7). These provide, for each year (going back to 1950)
and each age, the number of ﬁrst-borns. Although this data may
allow some comparisons, no hypothesis testing was performed for
this measure of childbearing, as the Dutch general population
was not considered to be an entirely appropriate standard. All stat-
istical analyses were performed with the SPSS statistical software
package (SPSS release 12.01).
Results
Centres
In the manner described earlier, 132 centres were identiﬁed
to be interested in participating. Eighty-one centres actually
started to enter patient data. One of these centres did not
continue as a result of a reorganization within the hospital;
another centre appeared not to have enough patients to
include. Thus, ultimately 79 centres participated in
26 countries.
Population
A total of 4168 cases were included. Forty-eight of the 79
participating centres were specialized (as mentioned
earlier). Details on participating centres as well as the
number of patients included per country are given in
the Appendix. Eighty-seven per cent of the patients were
included at specialized centres.
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After scrutiny of the data for completeness and consis-
tency, 4110 patients were selected for extensive analysis.
[58 cases (1.4%) were excluded].
Inclusion per defect is shown in Table 1. Median follow-up
was 5.1 (3.6–5.7 years) years. Status after 5 years of follow-
up was available for 3642 patients (89%). In 155 cases, the
patients were lost to follow-up prior to 5 years (4%),
whereas 306 patients had been referred to another centre
(7%). In seven cases (0.2%), the relevant item indicating
status in the CRF at the end of follow-up was missing.
The age distribution at baseline was strongly skewed, with
most patients in their twenties or thirties (see Table 1 ). The
overall median age was 27.9 (21.7–38.6) years and 79% of
the patients were aged ,50 years. As shown in Table 1,
median age varied per defect, reﬂecting the severity
of the condition. Thus, almost all (98%) Fontan and TGA
patients were aged ,40 vs. only half (52%) of ASD patients.
The oldest patient was an 87-year-old woman with an ASD.
Oldest patients in the remaining defects were aged 80
(Cyanotic defect), 57 (Fontan circulation), 72 (tetralogy of
Fallot), 74 (CoA), 62 (TGA), 77 (Marfan syndrome), and
77 years (VSD).
In addition, the proportion of females differed per defect.
In ASD, 67% of patients were females vs. only 39% in CoA
and TGA.
Clinical characteristics at baseline
In the last column of Table 1, for each defect the proportion
of patients displaying a certain characteristic relevant for
that speciﬁc defect (mainly relating to previous interven-
tions) is recorded.
The distribution of patients according to NYHA functional
class is shown in Table 2. Within the group of cyanotic
defects, Eisenmenger patients had a signiﬁcantly lower
exercise capacity compared with other cyanotic patients
(proportion of patients with NYHA Class greater than I,
93.7 vs. 79.7%; P, 0.001). Also recorded in Table 2 is the
medical history at inclusion regarding arrhythmias, endocar-
ditis, and vascular events. Supraventricular arrhythmias had
occurred in 18% of patients vs. 5% for ventricular arrhyth-
mias. Overall, 3% of patients were reported to have experi-
enced endocarditis, 4% cerebrovascular accidents/transient
ischaemic attacks (CVA/TIA), and 1% had a previous myocar-
dial infarction or had undergone percutaneous transluminal
coronary angioplasty or coronary artery bypass grafting (MI/
PTCA/CABG), but there were important differences among
the different defects. Prevalence of systemic arterial hyper-
tension (not shown in the table) was 4% for the group as a
whole, but as high as 46% in CoA and 17% in ASD.
Follow-up: mortality
A total of 115 patients (2.8%) died during the study period.
Table 3 provides the number of patients who died of any
cause (all-cause mortality) and those who died of cardiovas-
cular causes. In addition, the table gives 5 year mortality
rates and 95% conﬁdence intervals as estimated by the
Kaplan–Meier method. All-cause mortality was lowest in
patients with CoA, VSD, and ASD and highest in those with
cyanotic defect or Fontan circulation. The mode of death
was cardiovascular in the majority of patients (82% of all
deaths); cardiovascular death (as proportion of all-cause
mortality) was highest in patients with cyanotic defects,
Fontan circulation, tetralogy of Fallot, and VSD. The
Kaplan–Meier curve (see Figure 1 ) contrasts all-cause
mortality among the eight defects (log rank test, with
type of defect as factor: P, 0.0001), depicting survival
from study entry.
Follow-up: morbidity
Among patients with a follow-up of at least 3 years,
the NYHA functional class worsened in 6%. In cyanotic
defects and in the Fontan circulation, this occurred in
21 and 17%, respectively. In only 1% of CoA patients, the
NYHA class became worse. Among ASD patients, the NYHA
class improved more often than it worsened.
Pacemakers were inserted (at some time in the period
from before inclusion until the end of follow-up) in 6%
of patients, most frequently in TGA (22% of patients),
followed by the Fontan circulation (7%) and tetralogy
of Fallot (6%), and least frequently in Marfan syndrome
(1%). Twenty-seven patients were given an implantable
cardio-deﬁbrillator.
Overall, 713 of 3694 patients (19%) underwent surgery or a
catheter-based intervention (n ¼ 193) during follow-up. A
large proportion of these interventions consisted of the
closure of an ASD: 293 of 504 open ASDs were closed
during follow-up [of which 114 (39%) by a catheter-based
technique]. Not more than 21 of these 713 patients under-
went more than one procedure.
Findings regarding the number of outpatient visits and fre-
quency of investigations are shown in Table 4.
Table 1 Baseline characteristics
Inclusion (n) Agea Females (%) Defect-speciﬁc information
ASD II 882 39 (25–52) 67 43% closed
Ventricular septal defect 628 27 (20–36) 53 44% closed
Tetralogy of Fallot 811 26 (21–34) 48 40% transannular patch repair
CoA 551 26 (21–35) 39 90% previous repair
TGA 363 23 (20–27) 39 86% atrial switch procedure
Marfan syndrome 287 29 (22–38) 50 28% previous aortic intervention
Fontan circulation 198 23 (19–28) 45 60% tricuspid atresia
Cyanotic defect 390 29 (23–37) 62 60% Eisenmenger
Overall 4110 27 (23–37) 52
aValues presented are median (IQ range).
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Outpatient visits, expressed as the number of visits per
patient-year, showed that a patient visited the outpatient
clinic approximately three times per 2 years. Transthoracic
echography was the most frequent type of diagnostic pro-
cedure, and its use did not vary very much among the differ-
ent defects. Transoesophageal echocardiography was used
most frequently in ASD. Magnetic resonance imaging was
used most frequently in CoA and relatively infrequently in
Marfan syndrome. Holter monitoring was used most often
in Fontan circulation, tetralogy of Fallot, and TGA.
Use of medication (.3 months at some time during follow-
up) is speciﬁed for b-blockers, diuretics, anti-arrhythmic
agents, and anti-thrombotics in Table 5, which also indicates
the proportion of patients not using any kind of chronic
medication.
Pregnancy
Finally, Table 6 displays the proportion of females who had
at least one full-term pregnancy ever by the end of
follow-up. Also displayed in the same table are the corre-
sponding ﬁgures for an age-matched sample of the general
Dutch population (see Methods).
Discussion
The spectrum of adult CHD in Europe emerging from this
survey is one of a predominantly young population with sub-
stantial morbidity but relatively low mortality in a 5 year
period. The majority of patients have no or only mild func-
tional limitations. However, there are major differences
between the eight congenital heart conditions studied,
both in severity and regarding speciﬁc characteristics.
Outcomes are worst in cyanotic defects and in the Fontan cir-
culation, but a considerable proportion of patients in the
group of ‘milder’ defects also suffer from cardiac symptoms.
To our knowledge, this is the ﬁrst study reporting on the
functional status of a large group of patients and a range
of different defects. It is encouraging that the majority of
patients did not have severe functional limitations. More
than 60% of patients were in NYHA class I and only a small
proportion of patients were in class III or IV. Cyanotic
defects and the Fontan circulation are obviously among
the most severe congenital heart conditions, as was also
reﬂected in the mortality rates. Cyanosis due to an intract-
able right–left shunt is a multi-system disorder with a
chronic and progressive course.8 More than half of the
cyanotic patients had Eisenmenger syndrome, for which a
high mortality has been reported.9 Follow-up studies of
patients who underwent a Fontan operation have also
shown high mortality rates.10 In a recent study it was
found that, of 36 patients followed-up for a mean of
10 years, 28% had died.11
In contrast to these defects with prominent systemic
effects, mortality was low at the other end of the spectrum.
In particular, the mortality data on ASD indicate that some
of the older studies overestimated mortality.12,13
Notwithstanding the fact that, in general, functional class
was relatively good, a considerable proportion of patients
had a history of major morbidity at baseline, in particular,
arrhythmias, endocarditis, or a stroke/TIA. It is clear that
the course of CHD is marked by arrhythmias in a substantial
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part of the patient population. Arrhythmias are the most
frequent cause of hospitalization.14 We found that supraven-
tricular arrhythmias occurred in at least one of every ﬁve
patients, whereas one of every 20 patients experienced ven-
tricular arrhythmias. Differences in prevalence of arrhyth-
mias between the defects roughly reﬂect the different
pathological arrhythmogenic substrates. Arrhythmias are
known to be a frequently encountered problem in TGA,
Fontan circulation, and tetralogy of Fallot. In TGA, the exten-
sive damage to the atria which results from the atrial switch
procedures, is believed to be responsible for atrial ﬁbrilla-
tion/ﬂutter, sinus node dysfunction [sick sinus syndrome
occurred in 17% of the patients (not shown in the table)],
and atrioventricular conduction abnormalities (7%, not
shown).15 Ventricular arrhythmias are especially common in
Fallot patients, as is conﬁrmed by our data. ASDs and the
concomitant volume overload of the right atrium also fre-
quently cause arrhythmias. In a group of patients selected
for surgery, Gatzoulis et al.16 found a prevalence of 19%.
Unfortunately, operative closure introduces a new substrate
for arrhythmogenicity, and in patients with closed ASD the
incidence is still high. It is hoped that catheter-based
closure will reduce the occurrence of rhythm disturbances.
Because of the relative novelty of this technique, in our
cohort, only a minority of patients had undergone such
closure at the time of inclusion. However, for the closure of
the ASD during follow-up, already in nearly half (39%) of the
cases, a catheter-based method had been used.
Defects associated with the highest endocarditis risk
include unclosed VSDs, repaired tetralogy of Fallot, and cya-
notic conditions.17,18 The prevalence of a history of endocar-
ditis in cyanotic patients in our cohort (6%) was higher than
that reported in previous studies (e.g. Daliento et al.9 found
3.7% in their cohort). Moreover, in contrast to earlier
reports, cases of endocarditis did occur in Fontan circulation
and TGA corrected by Mustard repair. Although endocarditis
might be slightly over-represented in our cohort because of
the manner of selection of the patients for this survey (see
what follows), this large-scale study shows that endocarditis
remains an important complication.
The proportion of patients with a history of stroke/TIA in
the Fontan patients of our cohort was large compared with
what has been reported in the literature,19,20 although a
recent study found a cumulative incidence of thromboem-
bolic events of 25% in a 10 year (mean) follow-up period.11
It should be noted, however, that the events in some of
our cases might have taken place before the Fontan
procedure. In theory, the Fontan repair should remove one
important cause of thromboembolism, namely an open
connection between the right and left sides of the heart
(at least in Fontan procedures without a surgically created
fenestration). In contrast, supraventricular arrhythmias are
frequent after repair (discussed earlier), whereas some
types of Fontan operations introduce synthetic conduits
in the circulation. Moreover, the Fontan circulation is
known to be associated with abnormalities in the coagu-
lation proﬁle, which may lead both to thromboembolism
and bleeding complications.21 The issue of anti-coagulant
medication in Fontan patients therefore remains an important
dilemma in their clinical management.
The high prevalence of a history of stroke/TIA (10%) among
the cyanotic patients is noteworthy in the light of somewhat
conﬂicting reports in the literature. Perloff et al.22 followed
112 patients with cyanotic disease for a total of 748 patient-
years without observing a single stroke. In contrast, Ammash
and Warnes23 found that 13.6% of a group of 162 patients had
a history of a cerebrovascular event. Daliento et al.9 reported
that 7.9% of their Eisenmenger patients had experienced a
stroke. Apart from changes in the composition of the blood,
which result from hypoxemia (hyperviscosity, microcytosis),
interplay with other risk factors such as hypertension and
atrial ﬁbrillation appears to play a role in the increased
frequency of cerebrovascular events in this group of
patients. Also bleeding events occurred often. In our group,
Table 3 Mortality
n Number of deaths 5 year mortality
Cardiovascular Non-cardiovascular Kaplan-Meier estimate (%) 95% CI (%)
ASD II 882 5 4 1.1 0.3, 1.9
VSD 628 6 2 1.6 0.5, 2.7
Tetralogy of Fallot 811 8 3 1.3 0.5, 2.1
CoA 551 2 1 0.7 0.0, 1.4
TGA 363 9 0 3.0 1.0, 4.9
Marfan syndrome 287 3 2 1.7 0.0, 3.3
Fontan circulation 198 12 4 8.2 4.0, 12.3
Cyanotic defect 390 44 10 12.6 9.1, 16.0
Overall 4110 89 26 3.0 2.4, 3.5
Figure 1 Kaplan–Meier survival curves for the eight defects.
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the percentage of patients with bleeding problems was
almost equal to that of patients suffering from thrombotic
complications.
Hypertension did not seem to play an important role in the
patients of this survey, except in the case of CoA. In fact,
hypertension is a serious consequence of CoA and prevention
of its complications is a major principle of management. The
fact that in our cohort almost half of the CoA patients were
hypertensive is not exceptional. The relatively high preva-
lence of hypertension among ASD patients is probably
partly due to the higher age of this group, but a role for
pathophysiological mechanisms cannot be excluded.
It should be noted that the manner in which patients were
selected for this survey has introduced a bias towards a more
severe range of morbidity. This is especially apparent when
we consider the number of interventions performed. Thus,
the fact that almost 40% of ASD patients underwent an inter-
vention (mostly closure of their defect) is, of course, due to
the inclusion of most patients in specialized, often tertiary
referral centres. In contrast, the frequency of interventions
in adults with CHD underscores the need for staff with sufﬁ-
cient training and expertise. In our cohort, a considerable
proportion of patients had pacemakers, which should alert
us, again, to the prominence of (often complex) rhythm
disturbances. More than 20% of our sample of TGA patients
had a pacemaker inserted.
The use of medication is, to some extent, another indi-
cator of morbidity, although some drugs are prescribed for
prophylaxis. We found that more than half of the patients
were on some form of chronic medication. Among Fontan
patients, only 10% did not use drugs. However, even
among ASD patients, a signiﬁcant proportion of patients
did use drugs. The types of drugs used, of course, largely
reﬂect the prevalence of particular forms of morbidity
among the different defects. The high proportion of
Fontan patients using anti-thombotics and anti-arrhythmic
agents are a case in point. The use of anti-arrhythmic
agents and anti-thrombotics was more frequent than in pre-
viously reported studies.16 In line with current guidelines, a
large proportion of Marfan patients prophylactically used
b-blockers.24 The use of diuretics was especially high
among patients who are at risk for right-sided decompensa-
tion, in particular, patients with Fontan circulation, among
cyanotic patients and, in our sample, also ASD patients. It
is noteworthy that, even though the use of aspirin and cou-
marins is not generally recommended in cyanotic disease,
Table 5 Use of medication
No drugs Diuretics Beta-blocking
agents
Ace-
inhibitors
Anti-
arrhythmics
Anti-thrombotics
Coumarins Aspirin Other
anti-platelets
ASD II 42 (367/880) 20 (177) 18 (160) 18 (161) 11 (100) 21 (182/879) 17 (146) 1 (10)
VSD 64 (403/625) 11 (69) 12 (73) 15 (95) 4 (23) 9 (58/624) 4 (27) 0 (3)
Tetralogy of Fallot 56 (455/808) 14 (115) 17 (137) 13 (101) 12 (98) 11 (87/809) 7 (57) 1 (8)
CoA 42 (234/551) 11 (58) 38 (210) 22 (120) 3 (15) 11 (58/550) 5 (28) 1 (3)
TGA 43 (157/363) 16 (58) 17 (62) 33 (119) 12 (45) 18 (67/363) 7 (24) 1 (2)
Marfan syndrome 13 (38/287) 9 (25) 72 (208) 14 (41) 5 (14) 33 (92/283) 2 (6) 0 (1)
Fontan circulation 10 (20/198) 37 (73) 26 (51) 39 (77) 36 (71) 61 (120/198) 19 (38) 1 (1)
Cyanotic defect 23 (88/389) 37 (143) 11 (44) 16 (63) 17 (67) 23 (88/385) 18 (70) 2 (9)
Overall 43 (1762/4101) 18 (718) 23 (945) 19 (777) 11 (433) 18 (752/4091) 10 (396) 1 (37)
Values are percentage followed by numbers in parentheses. In the ﬁrst column the denominator of the fraction (k/n ) indicates the number of cases for
which data on drug use were available. Use of anti-thombotics was assessed separately. Use of medication means the use of drugs for at least 3 months
at any time prior to the end of follow-up.
Table 4 Follow-up evaluation: clinic visits and investigations
Outpatient visits TTE TEE MRI Holter
(visits/
patient-year)
(visits/100
patient-year)
(visits/100
patient-year)
(visits/100
patient-year)
(visits/100
patient-year)
ASD II 1.45 77 14 ,1 14
VSD 1.14 60 4 1 9
Tetralogy of Fallot 1.42 66 4 5 23
CoA 1.27 63 3 13 5
TGA 1.52 76 3 4 30
Marfan syndrome 1.37 87 6 2 6
Fontan circulation 1.92 88 8 5 33
Cyanotic defect 1.86 68 3 3 18
Overall 1.44 71 6 6 16
TTE, transthoracic echocardiography; TEE, transoesophageal echocardiography; MRI, magnetic resonance imaging; Holter, Holter monitoring.
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almost one out of every ﬁve cyanotic patients was using one
of these drugs.
The data on frequencies of diagnostic procedures and out-
patient visits provide an indication of the intervals at which
patients are actually being screened as part of regular
follow-up and of ‘the amount of care’ an adult CHD popu-
lation of a certain size needs. The issue of organization of
care and planning of future needs of this rapidly growing
population is one of the central concerns in the evolution
of the adult CHD discipline.
The age distribution of this population implies that most
women are in their reproductive age. As this survey was
not designed to assess the reproductive history of the
female patients in an exhaustive manner, the pregnancy
data collected were summarized into a simple measure.
Considering merely the proportion of females with at least
one full-term pregnancy, it seems that, in the case of the
less severe defects, childbearing is not very much affected
by the presence of the defect. It is remarkable, and testi-
mony to the success of the management of CHD, that,
after correction, TGA still allows a substantial proportion
of women to bear children.25 This is very different when cya-
nosis is present or when there is only one functional ventri-
cle. It should be noted that, generally, pregnancy is strongly
advised against in these conditions.26,27 How CHD affects
childbearing and vice versa is obviously an important and
complicated issue that requires more extensive research.
Finally, the demographic characteristics of our study
population are largely consistent with what is known at
present. The observation that the population is relatively
young is in line with the fact that only after the major
improvements in cardiac paediatric surgery in the middle
of the previous century did the majority of patients begin
to survive into adulthood. It is also apparent that patients
with more severe conditions with a high mortality, in par-
ticular, the Fontan circulation and cyanotic defects, are
even younger. Contrasts in the proportion of females
among patients with the different defects can largely be
traced to the differences in prevalence of the conditions
at birth,28 which suggest that mortality in the various
defects is not gender-related.
Limitations
One of the problems in studying adult CHD is the large
number of different lesions and clinical situations one may
encounter. In designing this survey, a compromise had to
be accepted between attempts at being comprehensive
and the necessity to limit the amount of data collected.
Therefore, it was decided to restrict the survey to eight of
the most common congenital conditions. However, even
under this restriction, in order to keep the CRF ‘manage-
able’, limitations had to be observed regarding the
amount of detail with which clinical characteristics and
medical history could be assessed.
Participation was on a voluntary basis and data entry
was done by the investigators on the basis of available
patient records. Thus,missing data constitute an unavoidable
aspect that might be a source of bias.
The vast majority of patients included in the survey were
being treated on a regular basis at a specialized centre for
adult CHD. Hence, the sample is to be considered as a ‘clini-
cal’ sample and, as such, not entirely representative of the
whole population of adults with CHD. For example, the fact
that a larger proportion of ASD patients (11%) were in NYHA
class III/IV than Fontan patients (9%) is largely due to the
method of patient selection. Many ASD patients were
included in the centres to which they were referred for
intervention. This is also illustrated by the improvements
in NYHA functional class over the follow-up period, which
are largely the result of interventions.
Conclusions
This EHS offered a unique opportunity to gain insight into
the spectrum of adult CHD throughout Europe. Its successful
completion has demonstrated the feasibility of large-scale
international studies in adult CHD and indicates that the dis-
cipline has become broadly established, catering to the
needs of an expanding relatively young population. With
more than 4000 patients included, the data presented
here form an important supplement to the currently avail-
able information that is largely derived from single insti-
tutions and a small number of patients with particular
defects. The ﬁndings of this study conﬁrm that morbidity
is high and emphasize the importance of specialized care
for the adult born with a heart defect.
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Aortic atresia, interrupted aortic arch type C perfused by bilateral arterial duct
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A non-syndromatic, 4.2 kg male newborn was admitted to the hospi-
tal at 24 h of age because of grunting and pale colour. Suspecting
cardiogenic shock, prostaglandin infusion was initiated with
prompt improvement of the clinical condition.
Echocardiography revealed a complex congenital heart disease.
There was an unbalanced atrioventricular septal defect with a
small left ventricle. There were bilateral superior caval veins, the
left draining to the coronary sinus. The pulmonary veins drained to
a collecting vessel which connected to the right atrium near its
junction with the right superior caval vein. The aortic valve is
atretic with a very small ascending aorta (AoA).
Catheterization showed a complex form of interrupted aortic
arch with a peculiar relationship to the pulmonary arteries. The
aortic arch was interrupted between the brachiocephalic trunk
(BCT) and the left common carotid artery (LCCA). Blood supply to
the very hypoplastic AoA and coronary arteries was provided by a
right arterial duct (RAD), connecting the right pulmonary artery
(RPA) and the BCT. This was nicely shown by retrograde injection
of the right radial artery (Panel A). Through a left arterial duct
(LAD), the descending aorta (AoD) was perfused as well as the
distal part of the aortic arch (Panel B). Panels C and D show all
great arteries and their relationship. Of particular interest is a
sharp angle at the origin of the BCT and the LCCA, suggesting
ﬁbrous continuity of the arch rather than complete interruption.
A bilateral duct is a rare ﬁnd. In this case of interrupted aortic
arch and aortic atresia, blood supply to the coronary arteries
depended on the patency of the RAD. Constriction of ductal tissue
in the ﬁrst hours after birth resulted in cardiac ischaemia and an early presentation with cardiogenic shock. Considering the complexity
of the malformation, no further therapy was offered.
Panel A. Retrograde injection in the right radial artery. Blood supply to the AoA from the RPA through the RAD and BCT.
Panel B. Injection in the AoD. Blood supply to the AoD and distal aortic arch, with LCCA and left subclavian artery, was provided by
an LAD.
Panel C. Injection in the LAD. LAD supplying the AoD and the distal arch. Right aortic arch supplying AoA. Fibrous continuity of arch
(arrow) suggested by sharp angle at the origin of the BCT and the LCCA (LPA, left pulmonary artery).
Panel D. Schematic representation of great arteries. Interrupted line, presumed ﬁbrous continuity of aortic arch.
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